×
About 1,524 results

ALLMedicine™ Prolactinoma Center

Research & Reviews  747 results

Long-term IGF-1 monitoring in prolactinoma patients treated with cabergoline might not ...
https://doi.org/10.1007/s12020-020-02557-1
Endocrine Andereggen L, Frey J et. al.

Dec 4th, 2020 - Cabergoline (CAB) therapy for prolactinomas has been associated with serum IGF-1 levels modifications, with recent reports indicating a paradoxical increase of IGF-1 levels during ongoing therapy. As a result, IGF-1 measurement has been proposed n...

Incidence of cabergoline associated valvulopathy in primary care patients with prolacti...
https://doi.org/10.1210/clinem/dgaa882
The Journal of Clinical Endocrinology and Metabolism; Stiles CE, Lloyd G et. al.

Nov 28th, 2020 - Controversy exists as to whether low-dose cabergoline is associated with clinically significant valvulopathy. Few studies examine hard cardiac end-point data, most relying on echocardiographic findings. To determine the prevalence of valve surgery...

MicroRNA-7a2 regulates prolactin in developing lactotrophs and prolactinoma cells.
https://doi.org/10.1210/endocr/bqaa220
Endocrinology LaPierre MP, Godbersen S et. al.

Nov 28th, 2020 - Prolactin production is controlled by a complex and temporally dynamic network of factors. Despite this tightly coordinated system, pathological hyperprolactinemia is a common endocrine disorder that is often not understood; thereby highlighting t...

Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resis...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646122
International Journal of Medical Sciences; Xiao Z, Yang X et. al.

Nov 11th, 2020 - Prolactinomas are the most common type of functional pituitary adenoma. Although bromocriptine is the preferred first line treatment for prolactinoma, resistance frequently occurs, posing a prominent clinical challenge. Both the prolactin receptor...

Pimozide augments bromocriptine lethality in prolactinoma cells and in a xenograft mode...
https://doi.org/10.3892/ijmm.2020.4784
International Journal of Molecular Medicine; Xiao Z, Liang J et. al.

Nov 6th, 2020 - As hyperprolactinemia is observed in patients with bromocriptine‑resistant prolactinoma, prolactin (PRL) has been implicated in the development of bromocriptine resistance. Since PRL primarily mediates cell survival and drug resistance via the Jan...

see more →

Clinicaltrials.gov  763 results

Long-term IGF-1 monitoring in prolactinoma patients treated with cabergoline might not ...
https://doi.org/10.1007/s12020-020-02557-1
Endocrine Andereggen L, Frey J et. al.

Dec 4th, 2020 - Cabergoline (CAB) therapy for prolactinomas has been associated with serum IGF-1 levels modifications, with recent reports indicating a paradoxical increase of IGF-1 levels during ongoing therapy. As a result, IGF-1 measurement has been proposed n...

Incidence of cabergoline associated valvulopathy in primary care patients with prolacti...
https://doi.org/10.1210/clinem/dgaa882
The Journal of Clinical Endocrinology and Metabolism; Stiles CE, Lloyd G et. al.

Nov 28th, 2020 - Controversy exists as to whether low-dose cabergoline is associated with clinically significant valvulopathy. Few studies examine hard cardiac end-point data, most relying on echocardiographic findings. To determine the prevalence of valve surgery...

MicroRNA-7a2 regulates prolactin in developing lactotrophs and prolactinoma cells.
https://doi.org/10.1210/endocr/bqaa220
Endocrinology LaPierre MP, Godbersen S et. al.

Nov 28th, 2020 - Prolactin production is controlled by a complex and temporally dynamic network of factors. Despite this tightly coordinated system, pathological hyperprolactinemia is a common endocrine disorder that is often not understood; thereby highlighting t...

Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resis...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646122
International Journal of Medical Sciences; Xiao Z, Yang X et. al.

Nov 11th, 2020 - Prolactinomas are the most common type of functional pituitary adenoma. Although bromocriptine is the preferred first line treatment for prolactinoma, resistance frequently occurs, posing a prominent clinical challenge. Both the prolactin receptor...

Pimozide augments bromocriptine lethality in prolactinoma cells and in a xenograft mode...
https://doi.org/10.3892/ijmm.2020.4784
International Journal of Molecular Medicine; Xiao Z, Liang J et. al.

Nov 6th, 2020 - As hyperprolactinemia is observed in patients with bromocriptine‑resistant prolactinoma, prolactin (PRL) has been implicated in the development of bromocriptine resistance. Since PRL primarily mediates cell survival and drug resistance via the Jan...

see more →

News  7 results

Prolactin, the pituitary, and pregnancy: Where’s the balance?
https://www.mdedge.com/familymedicine/article/164370/pituitary-thyroid-adrenal-disorders/prolactin-pituitary-and-pregnancy/page/0/3
Clinical Endocrinology News;

Apr 26th, 2018 - What if the tumor grows in pregnancy? During pregnancy, high estrogen levels from the placenta can stimulate prolactinoma growth, and the dopamine agonist’s inhibitory effect is gone once that medication’s been stopped. This means that “We have bo.

Pituitary Incidentaloma
https://www.mdedge.com/clinicianreviews/article/96669/endocrinology/pituitary-incidentaloma/page/0/1

Jan 26th, 2015 - SHOULD AN ASYMPTOMATIC PATIENT BE EVALUATED FURTHER? Endocrine Society guidelines2 recommend that all patients with pituitary incidentaloma, with or without symptoms, should undergo a complete history and physical examination and laboratory evalua.

Prolactinoma: A Case Study
https://www.mdedge.com/clinicianreviews/article/72153/endocrinology/prolactinoma-case-study/page/0/1

Nov 1st, 2011 - Dopamine agonists are approximately 80% to 90% effective in decreasing prolactin levels and reducing tumor size in microadenomas and 60% to 70% in macroadenomas. The major drawback of using medication is that it does not always provide permanent r.

Endocrine Society Releases Guidelines on Pituitary Incidentalomas
https://www.mdedge.com/internalmedicine/article/34059/endocrinology/endocrine-society-releases-guidelines-pituitary
Elizabeth Mechcatie

Apr 20th, 2011 - Surgical treatment of a pituitary incidentaloma is recommended when the lesion is causing a visual field deficit or other visual abnormalities, such as ophthalmoplegia "or neurological compromise," according to evidence-based clinical practice gui.

The Case of the Famous Woman With a Bloated Belly
https://www.medscape.com/viewarticle/714607_4

Jan 10th, 2010 - How Would Mary Have Been Treated Today? Today, when a woman suspects pregnancy, she undergoes a rapid test for pregnancy. If the result is negative but symptoms, such as galactorrhea or amenorrhea, are still present, an occult prolactinoma might b...

see more →

Patient Education  7 results see all →